688139 Qingdao Haier Biomedical Co., Ltd.
- 39.25
- -0.23-0.58%
Qingdao Haier Biomedical Co., Ltd. News
Investors Interested In Qingdao Haier Biomedical Co.,Ltd's (SHSE:688139) Earnings
With a median price-to-earnings (or "P/E") ratio of close to 30x in China, you could be forgiven for feeling indifferent about Qingdao Haier Biomedical Co.,Ltd's (SHSE:688139) P/E ratio of 30.7x. Ho
Shareholder Qi Jun Investment of Qingdao Haier Biomedical Co., Ltd. (688139.SH) has cumulatively reduced its shareholding in the company by 1.29%.
Qingdao Haier Biomedical Co., Ltd. (688139.SH) announced that on June 11, 2024, the company received a shareholder's notice from Ningbo...
Qingdao Haier Biomedical Co., Ltd. (688139.SH) did not repurchase its shares in May.
On May 2024, Qingdao Haier Biomedical Co., Ltd. (688139.SH) announced that the company did not repurchase shares through the Shanghai Stock Exchange trading system by centralized bidding trading. As of May 31, 2024, the company has accumulated repurchased 815,617 shares through the Shanghai Stock Exchange trading system, accounting for 0.26% of the company's total equity of 317,952,508 shares, with a highest repurchased price of 32.31 yuan/share and a lowest repurchased price of 27.40 yuan/share. The total amount paid was RMB 25,654,978.4.
Haier Biotech (688139.SH) will distribute the 2023 cash dividend of 0.515 yuan per share on June 6
Haier Biotech (688139.SH) announced that the company will release the 2023 annual report on June 6, 2024...
Is Qingdao Haier BiomedicalLtd (SHSE:688139) A Risky Investment?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that debt - which is usually involved in bankruptcies - is a very important factor, when
Haier Biotech (688139.SH): Major shareholder Qijun Investment plans to reduce the company's shares by no more than 1.6%
Haier Biotech (688139.SH) announced that the company holds 7.79% of the shares of Qijun in Ningbo Meishan Bonded Port Area...
Haier Biotech (688139.SH): Repurchase a total of 815,600 company shares
Gelonghui, May 6, 丨 Haier Biotech (688139.SH) announced that as of April 30, 2024, the company had repurchased a total of 815,617 shares through the Shanghai Stock Exchange trading system, accounting for 0.26% of the company's total share capital of 317,952,508 shares. The highest price of the repurchase transaction was RMB 32.31 per share, the lowest price was RMB 27.40 per share, and the total amount of capital paid was RMB 25,654,978.48 (excluding transaction fees).
Qingdao Haier Biomedical Co.,Ltd's (SHSE:688139) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Qingdao Haier BiomedicalLtd (SHSE:688139) has had a great run on the share market with its stock up by a significant 22% over the last month. Given that stock prices are usually aligned with a compa
Haier Biotech (688139.SH): Net profit of 138 million yuan in the first quarter increased 0.06% year over year
On April 25, GLONGHUI (688139.SH) released its first quarter report. Operating revenue was 687 million yuan, up 0.04% year on year, net profit of 138 million yuan, up 0.06% year on year, after deducting non-net profit of 130 million yuan, up 6.64% year on year, with basic earnings of 0.44 yuan per share.
Haier Biotech (688139.SH): 2.92 million restricted shares awarded to 262 incentive recipients
Gelonghui, April 18, 丨 Haier Biotech (688139.SH) announced that on April 18, 2024, the company held the 19th meeting of the 2nd board of directors, the 17th meeting of the 2nd board of directors, and the 2nd special meeting of independent directors to review and pass the “Proposal on Granting Restricted Shares for the First Time to Incentive Recipients”. It was determined that April 18, 2024 was the first grant date, and 2,920 million shares were awarded to 262 incentive recipients at an award price of 15.41 yuan/share.
Haier Biotech (688139.SH): A total cost of 25.488 million yuan to buy back 0.25% of the shares
Gelonghui, April 1, 丨 Haier Biotech (688139.SH) announced that as of March 31, 2024, the company had repurchased 809,606 shares of the company through centralized bidding transactions, accounting for 0.25% of the company's total share capital of 317,952,508 shares. The highest price of the repurchase transaction was 32.31 yuan/share, the lowest price was 29.55 yuan/share, and the total amount of capital paid was RMB 25,488,165.35 (not including transaction fees).
Downgrade: Here's How Analysts See Qingdao Haier Biomedical Co.,Ltd (SHSE:688139) Performing In The Near Term
The latest analyst coverage could presage a bad day for Qingdao Haier Biomedical Co.,Ltd (SHSE:688139), with the analysts making across-the-board cuts to their statutory estimates that might leave sha
Haier Biotech (688139.SH) plans to launch a 3.42 million restricted stock incentive plan
According to the Zhitong Finance App, Haier Biotech (688139.SH) disclosed the 2024 Restricted Stock Incentive Plan (draft). The number of restricted shares to be granted by the company under this incentive plan was 3.42 million shares, accounting for 1.076% of the company's total share capital of 317.9552.58 million shares when the draft incentive plan was announced. Among them, 2,920 million shares were granted for the first time, 50 million shares were reserved, and the grant price (including the reserved grant) was 15.41 yuan/share. The total number of incentive recipients granted for the first time in this incentive plan was 262, accounting for 2,636 employees in the company at the end of 2029
Haier Biotech (688139.SH) announced its 2023 annual results, with net profit of 406 million yuan, a year-on-year decrease of 32.41%
Haier Biotech (688139.SH) released its 2023 annual report. The company's revenue was 2.281 billion yuan,...
Is It Too Late To Consider Buying Qingdao Haier Biomedical Co.,Ltd (SHSE:688139)?
Qingdao Haier Biomedical Co.,Ltd (SHSE:688139), might not be a large cap stock, but it saw a significant share price rise of 21% in the past couple of months on the SHSE. Shareholders may apprec
Haier Biotech (688139.SH): cumulative repurchases of 792,700 shares
Gelonghui, March 1, 丨 Haier Biotech (688139.SH) announced that as of February 29, 2024, the company had repurchased 792,704 shares of the company through centralized bidding transactions, accounting for 0.25% of the company's total share capital of 317,952,508 shares. The highest price of the repurchase transaction was 32.31 yuan/share, the lowest price was 30.52 yuan/share, and the total amount of capital paid was RMB 24,984,395.46 (not including transaction fees).
Qingdao Haier Biomedical Co.,Ltd's (SHSE:688139) Market Cap Dropped CN¥671m Last Week; Individual Investors Who Hold 40% Were Hit as Were Institutions
Key Insights The considerable ownership by private companies in Qingdao Haier BiomedicalLtd indicates that they collectively have a greater say in management and business strategy 58% of the busines
Haier Biotech (688139.SH) performance report: 2023 net profit of 406 million yuan, a year-on-year decrease of 32.41%
Gelonghui, Feb. 26 | Haier Biotech (688139.SH) announced its 2023 annual performance report. Affected by factors such as the public health prevention and control business base for the same period and the current macro-environment and industry, the company achieved operating income of 2.281 billion yuan in 2023, down 20.36% from the same period last year. After excluding 587 million public health prevention and control businesses during the same period, core business revenue was slightly higher than the same period, and steady development was achieved under adverse external challenges. Net profit attributable to the owner of the parent company was 406 million yuan, a year-on-year decrease of 32.41%; not deducted from the owner of the parent company
Haier Biotech (688139.SH): Initial repurchase of 201,300 shares
On February 23, 2024, Haier Biotech (688139.SH) announced that on February 23, 2024, the company repurchased 201,250 shares of the company's shares for the first time through centralized bidding transactions, accounting for 0.06% of the company's total share capital of 317,952,508 shares. The highest price of the repurchase transaction was 32.31 yuan/share, the lowest price was 31.51 yuan/share, and the total amount of capital paid was RMB 6,414,305.46 (excluding transaction fees such as stamp duty and transaction fees).
Haier Biotech (688139.SH): Plans to repurchase 25 million yuan to 50 million yuan of company shares
Gelonghui, Feb. 8 | Haier Biotech (688139.SH) announced that the total amount of capital to be repurchased is not less than RMB 25 million, not more than RMB 50 million of the company's shares, calculated based on the maximum repurchase amount of RMB 50 million and the maximum repurchase price of 50 yuan/share. The number of shares repurchased is about 1 million shares, accounting for about 0.16% of the company's total share capital; according to the lower limit of the repurchase amount of RMB 25 million, the maximum repurchase price is estimated at 50 yuan/share. 0.31% of total share capital.
Analysis
Price Target
No Data
